​

Pfizer (PFE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PFE Stock Forecast

Pfizer stock forecast is as follows: an average price target of $32.83 (represents a 24.54% upside from PFE’s last price of $26.36) and a rating consensus of 'Hold', based on 21 wall street analysts offering a 1-year stock forecast.

PFE Price Target

The average price target for Pfizer (PFE) is $32.83 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $30.00. This represents a potential 24.54% upside from PFE's last price of $26.36.

PFE Analyst Ratings

Hold

According to 21 Wall Street analysts, Pfizer's rating consensus is 'Hold'. The analyst rating breakdown for PFE stock is 1 'Strong Buy' (4.76%), 8 'Buy' (38.10%), 11 'Hold' (52.38%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).

Pfizer Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Chris ShibutaniGoldman Sachs$33.00$28.4615.95%25.19%
Oct 17, 2024Courtney BreenBernstein$32.00$29.677.85%21.40%
Sep 25, 2024Carter GouldBarclays$32.00$28.9310.61%21.40%
Aug 07, 2024Narumi NakagiriDaiwa$34.00$28.8517.85%28.98%
Jul 31, 2024Mohit BansalWells Fargo$30.00$31.39-4.43%13.81%
Jul 31, 2024Chris ShibutaniGoldman Sachs$34.00$31.398.31%28.98%
Jul 30, 2024Vamil DivanGuggenheim$36.00$30.7217.19%36.57%
Jul 10, 2024Carter GouldBarclays$30.00$27.728.23%13.81%
May 22, 2024Evan SeigermanBMO Capital$36.00$29.6021.62%36.57%
Feb 14, 2024Louise ChenCantor Fitzgerald$45.00$26.9766.85%70.71%
Dec 14, 2023Thomas YehMorgan Stanley$20.00$26.93-25.72%-24.13%
Nov 27, 2023Terence FlynnMorgan Stanley$37.00$30.5021.31%40.36%
Feb 01, 2023Morgan Stanley$45.00$43.842.66%70.71%
Feb 01, 2023Credit Suisse$50.00$43.5914.71%89.68%
Feb 01, 2023Barclays$44.00$44.16-0.36%66.92%
Feb 01, 2023Atlantic Equities$46.00$44.164.17%74.51%
Feb 01, 2023Leerink Partners$48.00$44.168.70%82.09%
Dec 14, 2022Morgan Stanley$53.00$54.73-3.16%101.06%
Dec 13, 2022Chris ShibutaniGoldman Sachs$60.00$53.3712.42%127.62%
Nov 18, 2022Credit Suisse$55.00$48.3313.80%108.65%
May 23, 2022David RisingerLeerink Partners$55.00$52.884.01%108.65%
May 10, 2022Mohit BansalWells Fargo$54.42$19.11184.77%106.45%
May 09, 2022Mohit BansalWells Fargo$55.00$49.0412.15%108.65%
May 04, 2022Morgan Stanley$52.00$49.684.67%97.27%
May 02, 2022Vamil DivanMizuho Securities$55.00$49.0712.08%108.65%
Apr 15, 2022Louise ChenCantor Fitzgerald$75.00$53.1241.19%184.52%
Apr 10, 2022Terrance FlynnMorgan Stanley$55.00$55.17-0.31%108.65%
Apr 09, 2022Andrew BaumCitigroup$57.00$55.173.32%116.24%
Mar 12, 2022Geoff MeachamBank of America Securities$70.00$50.2739.25%165.55%
Feb 08, 2022Carter GouldBarclays$54.00$51.704.45%104.86%
Feb 08, 2022Chris SchottJ.P. Morgan$57.00$51.7010.25%116.24%
Feb 08, 2022Chris ShibutaniGoldman Sachs$50.00$51.70-3.29%89.68%
Jan 15, 2022Evan SeigermanBMO Capital$76.00$54.9538.31%188.32%
Jan 03, 2022Aaron GalBernstein$65.00$56.2215.62%146.59%
Dec 22, 2021Geoff PorgesLeerink Partners$56.00$59.10-5.25%112.44%
Dec 13, 2021Colin BristowUBS$60.00$54.789.53%127.62%
Nov 11, 2021Tobias GottschaltIndependent Research$54.00$49.808.43%104.86%
Nov 03, 2021Tim AndersonWolfe Research$46.00$44.094.33%74.51%
Jul 29, 2021Daniel BusbyRBC Capital$44.00$42.104.51%66.92%
Jun 01, 2021David ToungArgus Research$55.00$37.5446.51%108.65%

The latest Pfizer stock forecast, released on Oct 30, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $33.00, which represents a 15.95% increase from the stock price at the time of the forecast ($28.46), and a 25.19% increase from PFE last price ($26.36).

Pfizer Price Target by Period

1M3M12M
# Anlaysts-310
Avg Price Target-$32.33$34.20
Last Closing Price$26.36$26.36$26.36
Upside/Downside-100.00%22.65%29.74%

In the current month, the average price target of Pfizer stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pfizer's last price of $26.36. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024Goldman SachsBuyBuyHold
Oct 23, 2024Wells FargoMarket PerformMarket PerformHold
Oct 17, 2024BernsteinMarket PerformInitialise
Sep 25, 2024BarclaysEqual-WeightEqual-WeightHold
Sep 20, 2024Wells FargoEqual-WeightEqual-WeightHold
Sep 20, 2024Cantor FitzgeraldOverweightOverweightHold
Sep 13, 2024BMO CapitalOutperformOutperformHold
Jul 31, 2024Wells FargoEqual-WeightEqual-WeightHold
Jul 31, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 31, 2024Goldman SachsBuyBuyHold
Jul 30, 2024GuggenheimBuyInitialise
Jul 30, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 29, 2024RBC CapitalSector PerformSector PerformHold
Jul 15, 2024Cantor FitzgeraldOverweightOverweightHold
Jul 15, 2024BMO CapitalOutperformOutperformHold
Jul 12, 2024UBSNeutralNeutralHold
Jul 10, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 01, 2024Cantor FitzgeraldUnderperformUnderperformHold
Jul 01, 2024Morgan StanleyEqual-WeightEqual-WeightHold
May 28, 2024RBC CapitalCautiousDowngrade
May 22, 2024BMO CapitalOutperformOutperformHold
May 02, 2024Goldman SachsBuyBuyHold
Mar 01, 2024Truist FinancialUnderperformUnderperformHold
Mar 01, 2024UBSMarket PerformMarket PerformHold
Feb 14, 2024Cantor FitzgeraldOverweightOverweightHold
Jan 31, 2024UBSMarket PerformMarket PerformHold
Jan 29, 2024Wells FargoEqual-WeightEqual-WeightHold
Jan 29, 2024CitigroupNeutralNeutralHold
Jan 29, 2024Cowen & Co.OutperformMarket PerformDowngrade
Jan 12, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Dec 14, 2023BarclaysEqual-WeightEqual-WeightHold
Nov 27, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Nov 01, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Nov 01, 2023BarclaysEqual-WeightEqual-WeightHold
Oct 16, 2023Goldman SachsPositivePositiveHold
Oct 16, 2023Wells FargoEqual-WeightEqual-WeightHold
Sep 27, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Aug 28, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Jun 29, 2023Credit SuisseOutperformNeutralDowngrade
May 03, 2023BarclaysEqual-WeightEqual-WeightHold
Mar 14, 2023BarclaysEqual-WeightEqual-WeightHold
Feb 23, 2023SVB LeerinkMarket PerformMarket PerformHold
Feb 07, 2023DaiwaOutperformUpgrade
Feb 01, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Feb 01, 2023BMO CapitalOutperformOutperformHold
Feb 01, 2023BarclaysEqual-WeightEqual-WeightHold
Feb 01, 2023Atlantic EquitiesNeutralNeutralHold
Feb 01, 2023SVB LeerinkMarket PerformMarket PerformHold
Jan 17, 2023Wells FargoOverweightReduceDowngrade
Dec 14, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Dec 13, 2022Goldman SachsNeutralBuyUpgrade
Nov 18, 2022Credit SuisseOutperformInitialise
Nov 02, 2022Wells FargoOverweightOverweightHold
Oct 12, 2022BarclaysEqual-WeightEqual-WeightHold
Oct 12, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Oct 11, 2022SVB LeerinkMarket PerformMarket PerformHold
Jul 28, 2022Cowen & Co.OutperformOutperformHold
Jul 28, 2022Cantor FitzgeraldOverweightOverweightHold
Jun 30, 2022SVB LeerinkMarket PerformMarket PerformHold
Jun 20, 2022JefferiesBuyUpgrade
May 23, 2022SVB LeerinkMarket PerformInitialise
May 09, 2022Wells FargoBuyBuyHold
May 03, 2022Piper SandlerUnderweightDowngrade
Apr 14, 2022Cantor FitzgeraldOverweightOverweightHold
Feb 14, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jan 30, 2022CFRAStrong BuyStrong BuyHold
Jan 15, 2022BMO CapitalOutperformOutperformHold
Jan 02, 2022BenchmarkBuyBuyHold
Dec 18, 2021Goldman SachsNeutralInitialise
Dec 10, 2021BarclaysEqual-WeightEqual-WeightHold
Nov 14, 2020Mizuho SecuritiesBuyBuyHold

Pfizer's last stock rating was published by Goldman Sachs on Oct 30, 2024. The company gave PFE a "Buy" rating, the same as its previous rate.

Pfizer Financial Forecast

Pfizer Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$13.23B$12.73B$18.28B$24.29B$22.64B$27.74B$25.66B$23.64B$24.09B$18.98B$14.58B$5.95B$12.13B$11.80B$12.03B$12.69B$12.68B$13.26B$13.12B$12.91B$12.78B
Avg Forecast$19.14B$16.21B$14.11B$14.66B$17.41B$14.92B$12.96B$13.87B$14.37B$13.34B$13.36B$16.61B$24.38B$21.07B$25.49B$24.10B$24.16B$22.58B$18.71B$13.65B$11.67B$12.31B$11.54B$11.81B$12.61B$12.26B$13.40B$12.99B$12.57B$12.41B
High Forecast$19.67B$16.66B$14.50B$14.73B$17.96B$14.93B$12.96B$13.87B$14.77B$14.85B$13.73B$17.07B$25.05B$21.07B$25.49B$24.10B$24.16B$22.58B$18.71B$13.65B$11.67B$12.31B$11.54B$11.81B$12.61B$12.26B$13.40B$12.99B$15.08B$14.89B
Low Forecast$18.16B$15.38B$13.38B$14.58B$17.00B$14.91B$12.96B$13.87B$14.13B$12.24B$12.68B$15.76B$23.13B$21.07B$25.49B$24.10B$24.16B$22.58B$18.71B$13.65B$11.67B$12.31B$11.54B$11.81B$12.61B$12.26B$13.40B$12.99B$10.06B$9.93B
# Analysts1113115336108878889999999955551219
Surprise %---------0.99%0.95%1.10%1.00%1.07%1.09%1.06%0.98%1.07%1.01%1.07%0.51%0.99%1.02%1.02%1.01%1.03%0.99%1.01%1.03%1.03%

Pfizer's average Quarter revenue forecast for Dec 23 based on 6 analysts is $14.37B, with a low forecast of $14.13B, and a high forecast of $14.77B. PFE's average Quarter revenue forecast represents a 8.59% increase compared to the company's last Quarter revenue of $13.23B (Sep 23).

Pfizer EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113115336108878889999999955551219
EBITDA---------$-803.00M$4.21B$8.40B$7.56B$11.25B$13.31B$11.52B$5.32B$9.50B$8.25B$7.24B$1.42B$3.85B$5.57B$5.48B$282.00M$12.69B$6.05B$6.22B$5.99B$5.81B
Avg Forecast$6.24B$5.28B$4.60B$4.78B$5.67B$4.86B$4.22B$7.96B$4.68B$4.35B$4.36B$8.52B$3.63B$7.09B$8.58B$9.11B$8.13B$7.60B$6.30B$5.74B$3.93B$4.14B$3.89B$4.96B$4.24B$4.13B$4.51B$5.39B$5.83B$5.63B
High Forecast$6.41B$5.43B$4.72B$4.80B$5.85B$4.87B$4.22B$9.56B$4.81B$4.84B$4.48B$10.22B$4.35B$7.09B$8.58B$10.93B$8.13B$7.60B$6.30B$6.89B$3.93B$4.14B$3.89B$5.95B$4.24B$4.13B$4.51B$6.47B$7.00B$6.76B
Low Forecast$5.92B$5.01B$4.36B$4.75B$5.54B$4.86B$4.22B$6.37B$4.61B$3.99B$4.13B$6.81B$2.90B$7.09B$8.58B$7.29B$8.13B$7.60B$6.30B$4.59B$3.93B$4.14B$3.89B$3.97B$4.24B$4.13B$4.51B$4.31B$4.67B$4.51B
Surprise %----------0.18%0.97%0.99%2.08%1.59%1.55%1.26%0.65%1.25%1.31%1.26%0.36%0.93%1.43%1.11%0.07%3.07%1.34%1.15%1.03%1.03%

10 analysts predict PFE's average Quarter EBITDA for Sep 23 to be $4.35B, with a high of $4.84B and a low of $3.99B. This is 3.28% upper than Pfizer's previous annual EBITDA (Jun 23) of $4.21B.

Pfizer Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113115336108878889999999955551219
Net Income---------$-2.38B$2.33B$5.54B$5.00B$8.61B$9.91B$7.86B$3.85B$8.15B$5.56B$4.88B$594.00M$2.19B$3.43B$3.40B$-336.00M$7.68B$5.05B$3.88B$3.56B$3.12B
Avg Forecast$4.71B$4.38B$3.23B$4.03B$2.73B$3.51B$2.61B$5.94B$-902.76M$-455.48M$3.25B$6.35B$2.31B$7.90B$9.82B$6.79B$4.98B$6.13B$5.53B$3.86B$2.87B$4.07B$3.85B$3.07B$3.28B$3.52B$4.29B$3.37B$3.47B$3.03B
High Forecast$4.88B$4.54B$3.35B$4.35B$3.53B$3.58B$2.61B$7.13B$-475.14M$-313.14M$3.37B$7.62B$2.78B$8.23B$9.82B$8.15B$4.98B$6.13B$5.64B$4.64B$2.87B$4.07B$3.85B$3.69B$3.28B$3.52B$4.29B$4.04B$4.16B$3.63B
Low Forecast$4.40B$4.09B$3.02B$3.71B$2.09B$3.43B$2.61B$4.75B$-1.33B$-683.23M$3.04B$5.08B$1.85B$7.57B$9.82B$5.44B$4.98B$6.13B$5.41B$3.09B$2.87B$4.07B$3.85B$2.46B$3.28B$3.52B$4.29B$2.69B$2.77B$2.42B
Surprise %---------5.23%0.72%0.87%2.16%1.09%1.01%1.16%0.77%1.33%1.01%1.26%0.21%0.54%0.89%1.11%-0.10%2.18%1.18%1.15%1.03%1.03%

Pfizer's average Quarter net income forecast for Sep 23 is $-455.48M, with a range of $-683.23M to $-313.14M. PFE's average Quarter net income forecast represents a -119.57% decrease compared to the company's last Quarter net income of $2.33B (Jun 23).

Pfizer SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113115336108878889999999955551219
SG&A---------$3.28B$3.50B$3.42B$4.64B$3.39B$3.05B$2.59B$4.09B$2.90B$2.93B$2.78B$2.70B$3.02B$2.81B$2.74B$4.24B$3.26B$3.51B$3.34B$3.41B$3.31B
Avg Forecast$4.21B$3.56B$3.10B$3.22B$3.83B$3.28B$2.85B$1.96B$3.16B$2.93B$2.94B$2.09B$2.79B$4.61B$5.58B$2.24B$5.29B$4.94B$4.09B$2.20B$2.55B$2.69B$2.53B$2.48B$2.76B$2.68B$2.93B$2.89B$3.32B$3.21B
High Forecast$4.32B$3.66B$3.19B$3.24B$3.95B$3.28B$2.85B$2.35B$3.25B$3.27B$3.02B$2.51B$3.34B$4.61B$5.58B$2.69B$5.29B$4.94B$4.09B$2.65B$2.55B$2.69B$2.53B$2.98B$2.76B$2.68B$2.93B$3.47B$3.99B$3.85B
Low Forecast$3.99B$3.38B$2.94B$3.21B$3.74B$3.28B$2.85B$1.57B$3.11B$2.69B$2.79B$1.68B$2.23B$4.61B$5.58B$1.79B$5.29B$4.94B$4.09B$1.76B$2.55B$2.69B$2.53B$1.98B$2.76B$2.68B$2.93B$2.32B$2.66B$2.57B
Surprise %---------1.12%1.19%1.63%1.67%0.74%0.55%1.16%0.77%0.59%0.72%1.26%1.06%1.12%1.11%1.11%1.54%1.21%1.20%1.15%1.03%1.03%

Pfizer's average Quarter SG&A projection for Dec 23 is $3.16B, based on 6 Wall Street analysts, with a range of $3.11B to $3.25B. The forecast indicates a -3.69% fall compared to PFE last annual SG&A of $3.28B (Sep 23).

Pfizer EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113115336108878889999999955551219
EPS---------$-0.42$0.41$0.98$0.89$1.54$1.77$1.40$0.69$1.45$0.99$0.87$0.11$0.39$0.62$0.61$-0.06$1.38$0.91$0.69$0.60$0.52
Avg Forecast$0.83$0.77$0.57$0.71$0.48$0.61$0.46$0.52$-0.16$-0.08$0.57$0.98$1.05$1.39$1.72$1.49$0.87$1.08$0.97$0.78$0.50$0.71$0.68$0.73$0.58$0.62$0.75$0.75$0.73$0.65
High Forecast$0.86$0.80$0.59$0.76$0.62$0.63$0.46$0.52$-0.08$-0.05$0.59$1.02$1.08$1.45$1.72$1.53$0.87$1.08$0.99$0.78$0.50$0.71$0.68$0.73$0.58$0.62$0.75$0.75$0.88$0.78
Low Forecast$0.77$0.72$0.53$0.65$0.37$0.60$0.46$0.51$-0.23$-0.12$0.53$0.92$0.98$1.33$1.72$1.46$0.87$1.08$0.95$0.78$0.50$0.71$0.68$0.73$0.58$0.62$0.75$0.75$0.58$0.52
Surprise %---------5.26%0.72%1.00%0.85%1.11%1.03%0.94%0.79%1.35%1.02%1.12%0.22%0.55%0.92%0.83%-0.10%2.23%1.21%0.92%0.82%0.80%

According to 10 Wall Street analysts, Pfizer's projected average Quarter EPS for Sep 23 is $-0.08, with a low estimate of $-0.12 and a high estimate of $-0.05. This represents a -119.47% decrease compared to PFE previous annual EPS of $0.41 (Jun 23).

Pfizer Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$100.06$135.8335.75%Buy
LLYEli Lilly and Company$778.62$1.03K31.80%Buy
AMGNAmgen$265.95$338.2227.17%Buy
PFEPfizer$26.43$32.8324.21%Hold
ABBVAbbVie$175.38$211.2020.42%Buy
JNJJohnson & Johnson$146.41$175.1319.62%Buy
GILDGilead Sciences$92.80$87.30-5.93%Buy
BMYBristol-Myers Squibb Company$57.65$50.50-12.40%Hold

PFE Forecast FAQ

Is Pfizer a good buy?

No, according to 21 Wall Street analysts, Pfizer (PFE) is considered a 'Hold'. The rating consensus is based on 1 'Strong Buy' and 8 'Buy' recommendations, accounting for 42.86% of PFE's total ratings.

What is PFE's price target?

Pfizer (PFE) average price target is $32.83 with a range of $30 to $36, implying a 24.54% from its last price of $26.36. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pfizer stock go up soon?

According to Wall Street analysts' prediction for PFE stock, the company can go up by 24.54% (from the last price of $26.36 to the average price target of $32.83), up by 36.57% based on the highest stock price target, and up by 13.81% based on the lowest stock price target.

Can Pfizer stock reach $40?

PFE's average twelve months analyst stock price target of $32.83 does not support the claim that Pfizer can reach $40 in the near future.

What are Pfizer's analysts' financial forecasts?

Pfizer's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $59.17B (high $59.72B, low $58.75B), average EBITDA is $22.73B (high $24.5B, low $21B), average net income is $14.78B (high $16.85B, low $12.88B), average SG&A $11.92B (high $12.43B, low $11.44B), and average EPS is $2.07 (high $2.22, low $1.94). PFE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.11B (high $65.55B, low $61.5B), average EBITDA is $20.9B (high $21.37B, low $20.04B), average net income is $16.36B (high $17.12B, low $15.21B), average SG&A $14.1B (high $14.42B, low $13.52B), and average EPS is $2.87 (high $3, low $2.67).

Did the PFE's actual financial results beat the analysts' financial forecasts?

Based on Pfizer's last annual report (Dec 2022), the company's revenue was $100.33B, beating the average analysts forecast of $95.04B by 5.57%. Apple's EBITDA was $43.64B, beating the average prediction of $28.41B by 53.60%. The company's net income was $31.37B, beating the average estimation of $26.83B by 16.92%. Apple's SG&A was $13.68B, missing the average forecast of $15.22B by -10.13%. Lastly, the company's EPS was $5.59, missing the average prediction of $5.65 by -1.09%. In terms of the last quarterly report (Sep 2023), Pfizer's revenue was $13.23B, missing the average analysts' forecast of $13.34B by -0.81%. The company's EBITDA was $-803M, missing the average prediction of $4.35B by -118.47%. Pfizer's net income was $-2.382B, beating the average estimation of $-455M by 422.97%. The company's SG&A was $3.28B, beating the average forecast of $2.93B by 11.84%. Lastly, the company's EPS was $-0.42, beating the average prediction of $-0.0798 by 426.07%